Turk İlaç ve Serum Sanayi A.Ş. stated that it has put into effect an exclusive agreement under which CEO Pharma will act as the sole authorized party for marketing and distribution activities in the pharmacy channel. The company confirmed that the agreement became effective as of January 6, 2026.
According to the disclosure, the marketing and distribution of all pharmaceuticals manufactured at Turk İlaç’s facilities for the pharmacy market will be carried out by CEO Pharma. Turk İlaç expects this collaboration to strengthen its presence in the pharmacy channel and support growth in both turnover and EBITDA.
Company Statement (PDP Disclosure)
“An exclusivity agreement has been signed with CEO Pharma Pharmaceutical Wholesaler for the marketing and distribution of all medicines manufactured at Turk İlaç ve Serum Sanayi A.Ş. facilities in the pharmacy market. We expect this agreement to contribute by increasing the share of our products in the pharmacy market, thereby boosting our turnover and EBITDA.”
Source: Borsagundem
